GSK’s mepolizumab succeeds in phase 3 trial in hypereosinophilic syndrome
The late-stage study evaluated subcutaneously administered mepolizumab 300mg (3x100mg) every four weeks against placebo in 108 adolescent and adult patients with severe HES. The HES trial met its